New shot could tame tough eczema in large trial
NCT ID NCT06468956
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial tests an experimental injection called SHR-1819 in 652 adults with moderate to severe atopic dermatitis (eczema). Half get the drug, half get a placebo. The main goal is to see if it improves skin rash and itch after 16 weeks. If it works, it may offer a new way to control this chronic skin condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1819 injection
- What this could lead to
- If successful, this could provide a new treatment option to control moderate to severe atopic dermatitis, reducing skin inflammation and itch.
- What could go wrong
- This is still an experimental drug. Even in Phase 3, it may not prove more effective than placebo, and side effects are possible. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Fudan University HuaShan Hospital
Shanghai, Shanghai Municipality, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill tame tough eczema? a large trial aims to find out
- New shot could tame tough eczema by calming overactive immune cells
- New drug aims to calm severe eczema without steroids
- New drug shows promise for severe eczema in toddlers
- Eczema drug nemolizumab put to the vaccine test
- New shot could tame severe eczema in kids